Can a double-dose of quit-smoking meds help pancreatitis patients kick the habit?

NCT ID NCT07171112

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests whether increasing the dose of varenicline or adding bupropion helps people with recurrent acute or chronic pancreatitis quit smoking. All 45 participants start with standard varenicline; those still smoking after 6 weeks are randomly assigned to a higher dose, a combination, or continued standard dose. Success is measured by self-report and breath carbon monoxide levels at 12 and 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Varenicline and bupropion
What this could lead to
If successful, this could provide a tailored smoking cessation strategy for people with pancreatitis, potentially reducing disease flares and complications.
What could go wrong
This is a small Phase 2 trial with only 45 participants, so results may not apply broadly. The higher drug doses may cause more side effects, and quitting smoking is difficult even with medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATITIS, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.